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Abstract
Objective: Electronic health record (EHR) systems contain structured data (such as diagnostic 
codes) and unstructured data (clinical documentation). Clinical insights can be derived from 
analyzing both. The use of natural language processing (NLP) algorithms to effectively analyze 
unstructured data has been well demonstrated. Here we examine the utility of NLP for the 
identification of patients with non-alcoholic fatty liver disease, assess patterns of disease 
progression, and identify gaps in care related to breakdown in communication among providers.
Materials and Methods: All clinical notes available on the 38,575 patients enrolled in the 
Mount Sinai BioMe cohort were loaded into the NLP system. We compared analysis of structured 
and unstructured EHR data using NLP, free-text search, and diagnostic codes with validation 
against expert adjudication. We then used the NLP findings to measure physician impression of 
progression from early-stage NAFLD to NASH or cirrhosis. Similarly, we used the same NLP 
findings to identify mentions of NAFLD in radiology reports that did not persist into clinical 
notes.
Results: Out of 38,575 patients, we identified 2,281 patients with NAFLD. From the remainder, 
10,653 patients with similar data density were selected as a control group. NLP outperformed ICD 
and text search in both sensitivity (NLP: 0.93, ICD: 0.28, text search: 0.81) and F2 score (NLP: 
0.92, ICD: 0.34, text search: 0.81). Of 2281 NAFLD patients, 673 (29.5%) were believed to have 
progressed to NASH or cirrhosis. Among 176 where NAFLD was noted prior to NASH, the 
average progression time was 410 days. 619 (27.1%) NAFLD patients had it documented only in 
radiology notes and not acknowledged in other forms of clinical documentation. Of these, 170 
(28.4%) were later identified as having likely developed NASH or cirrhosis after a median 1057.3 
days.
Discussion: NLP-based approaches were more accurate at identifying NAFLD within the EHR 
than ICD/text search-based approaches. Suspected NAFLD on imaging is often not acknowledged 
in subsequent clinical documentation. Many such patients are later found to have more advanced 
liver disease. Analysis of information flows demonstrated loss of key information that could have 
been used to help prevent the progression of early NAFLD (NAFL) to NASH or cirrhosis.
Conclusion: For identification of NAFLD, NLP performed better than alternative selection 
modalities and facilitated. It then facilitated analysis of knowledge flow between physician and 
enabled the identification of breakdowns where key information was lost that could have slowed or 
prevented later disease progression.
Keywords
Natural Language Processing; Patient Safety; NAFLD
1 INTRODUCTION
Artificial intelligence has shown increasing promise when applied identification and 
prediction of countless medical outcomes. When applied to clinician workflow, it provides a 
form of augmented intelligence, aiding clinicians with decision support and error avoidance. 
These applications have predominantly been built leveraging only structured data because of 
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its availability and ease of interpretation, however unstructured data (such as dictated notes) 
contain critical clinical information and thereby offer the potential to greatly enhance 
clinical insights than can be derived from use of structured data alone. Several public and 
proprietary approaches have been taken to developing natural language processing (NLP) 
systems to make sense of unstructured clinical data.[1,2] NLP approaches have been used 
successfully for biomedical research such as accurate phenotyping of complex diseases and 
for clinical tasks including identification of patients with NAFLD.[11][12] Here we examine 
the use of one SNOMED-based NLP tool for extracting patient features related non-
alcoholic fatty liver disease (NAFLD). NAFLD represents a spectrum of liver diseases 
characterized histologically by macrovesicular fat and ranging in severity from nonalcoholic 
fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH).[3,4] A subset of patients with 
NAFLD progresses to cirrhosis and has an increased risk of hepatocellular carcinoma and 
liver-related mortality.[3] NAFLD is emerging as one of the most common causes of liver 
failure in the United States.[5] Multiple professional societies have published guidelines for 
the diagnosis and management of patients with NAFLD.[6] NAFLD is suspected in patients 
with metabolic syndrome, hepatomegaly, or mild elevations in aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels. However, normal levels of AST and ALT 
do not exclude the presence of NAFLD and hepatomegaly is found only in approximately 
20% of patients.[8,9] A key component in the diagnosis of NAFLD is evidence of hepatic 
steatosis on imaging or biopsy. Many patients have abdominal or chest imaging performed 
for unrelated disorders which may incidentally find hepatic steatosis and allow for 
additionally workup for NAFLD including exclusion of other chronic liver diseases and 
alcohol consumption. The rapid and accurate identification of NAFLD by NLP from 
unstructured text such as radiology reports is one potential method to address the gap 
between incidental findings and patient care.
We first assess the accuracy of NLP against other simpler approaches to derive insights into 
the treating clinician’s understanding of the patient. We then determine the ability of NLP to 
track the diagnostic process and identify potential breakdowns. We determine the proportion 
of patients with fatty liver documented in radiology reports in which the presumptive 
diagnosis was also documented in a progress note from a healthcare provider. Second, to 
identify communication breakdowns at the point of care, we examine patients where 
NAFLD was identified in radiology notes but never referenced in progress note. While we 
focused our approach on NAFLD, the methodology is broadly applicable to other disease 
processes.
2 MATERIALS & METHODS
2.1 Study setting and population
The study was conducted at the Icahn School of Medicine at Mount Sinai and used the data 
resources of the BioMe Biobank at the Charles Bronfman Institute of Personalized 
Medicine. [13] The BioMe Biobank is a prospective cohort study with over 40,000 
ethnically diverse patients recruited from primary care and subspecialty clinics within the 
Mount Sinai Health System, used for a diverse range of associated studies.[14–17] BioMe 
has no inclusion or exclusion criteria beyond that they must be able to enroll themselves. 
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Open enrollment is conducted at multiple Mount Sinai Hospitals around greater New York 
City, resulting in one of the most genetically diverse biobanks created. The Institutional 
Review Board approved the study and informed consent was obtained for all subjects. All 
patient notes are uploaded weekly to BioMe servers, with notes dating back to 2007.
2.2 Data preparation: Natural Language Processing
We extracted the clinical documentation for all BioMe participants from the centralized 
DataMart up to December 31, 2017, with the sample starting June 11, 2009. Enrollment 
times for each patient was relatively random as it was a continuous process. Patients 
remained enrolled until their 18th birthday (at which point they have to re-enroll) or they 
died. Clinical documentation was comprised of progress notes, radiology reports, discharge 
summaries and pathology reports. We then applied the CLiX clinical NLP engine produced 
by Clinithink (see Appendix for more information) to this cohort, an algorithm recently 
demonstrated to be useful in patient phenotyping.[18] CLiX is a general-purpose stochastic 
parser, which maps patient facts described in clinical narrative to post-coordinated 
SNOMED expressions, thereby creating a highly descriptive, standardized data layer 
capturing all identified clinical facts across domains and clinical contexts.[19] SNOMED 
expressions are based on SNOMED CT, a granular, hierarchical, general-purpose clinical 
terminology combining the most comprehensive single English terminology for medicine. 
The SNOMED compositional grammar then specifies how concepts should be combined as 
expressions, making it possible to describe the clinical context around the core concept with 
modifiers such as laterality, certainty, tense, negation or the person being discussed. The 
combinatorial effect allows for substantially more expressivity than possible with single 
concepts with post-coordination.[19] For example, a condition mentioned as part of a 
differential diagnosis will be assigned a Finding context of Probably present, while when 
expressed definitively, it will be assigned Known present. While SNOMED (the 2016 US 
edition) has approximately 430,000 concepts, the NLP system identified 6,665,726 unique 
expressions to describe 420,181,346 total findings on the patients in this cohort. 
Supplementary Appendix Figure 1 demonstrates the SNOMED expressions identified for a 
sample phrase, and how the core concepts fit into the SNOMED CT terminology.
To identify patients matching specific criteria, we used a SNOMED query engine (a second 
component of CLiX) to perform hierarchical subsumption queries identifying relevant 
SNOMED expressions, meaning the identification of all SNOMED expressions found for 
the patient that were logical descendants (according to the SNOMED CT hierarchy) of each 
query expression. For example, according to SNOMED, NAFLD is a great-grandchild of 
Disease of liver and the temporal context of Current or past is a child of Temporal context 
value. The complete query for patients known to have had some form of liver disease is 
shown in Figure 1.
We used a SNOMED browser to identify other concepts critical to the identification of 
patients with NAFLD that were not SNOMED descendants of NAFLD to ensure that our 
queries captured patients with all concepts appropriate for the analysis. This led us to 
conclude that the optimal method would be to search for patients with the NAFLD parent, 
Steatosis of liver, and exclude diagnoses other than NAFLD. As a result, we excluded 
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patients with Wilson disease, abetalipoproteinemia, alcoholic fatty liver, alcoholism (e.g. 
problem drinker, very heavy drinker, heavy drinker) and hepatitis B and C using a 
combination of NLP and ICD9/10 criteria.
2.3 Manual Review Study Design
In order to assess the accuracy of NAFLD patient selection, we performed a manual review 
on three different methods for patient selection. The study design is shown in Figure 2.
After parsing the notes using NLP queries as described above, we conducted a simple text 
search for pre-defined phrases pertaining to NAFLD.
2.3.1 ICD Codes and Simple Text Search to Identify NAFLD—We compared 
NLP-based approaches to searching structured data and simpler text-based approaches for 
identifying NAFLD within the EHR. As there is not ICD code for NAFLD itself, structured 
search looked for patients with ICD-9-CM and ICD-10-CM codes commonly used for 
NAFLD, [20–22] including:
• ICD-9-CM 571.8: Other chronic nonalcoholic liver disease
• ICD-9-CM 571.9: Unspecified chronic liver disease without mention of alcohol
• ICD-10-CM K76.0: Fatty (change of) liver, not elsewhere classified
• ICD-10-CM K75.81: Nonalcoholic steatohepatitis (NASH)
• ICD-10-CM K75.89: Other specified inflammatory liver diseases
Unstructured search used SQL on raw patient notes to identify patients with notes containing 
phrases indicative of NAFLD to see how well patients could be identified from notes 
without full NLP assessing negation, context, etc. Text search was performed for “NAFLD”, 
“NASH”, “fatty liver”, “steatosis”, “steatohepatitis”, “fatty infiltration of the liver” and 
“fatty infiltration of liver”.
2.3.2 Comparison with Manual Validation through Chart Abstraction—We 
compared all approaches (NLP/text search/ICD) to manual validation using blinded manual 
chart review. Two physicians independently, without knowing case/control status, reviewed 
all records on 200 patients, 100 case patients identified as having NAFLD and 100 randomly 
(from a similar cohort, as explained below) selected patients identified as controls. Patients 
were classified as cases or controls based on clinical criteria. A clinical diagnosis of NAFLD 
required 1) the presence of fatty infiltration of the liver on imaging, 2) exclusion of hepatitis 
C infection, 3) absence of documented alcohol abuse. For controls, we randomly selected 
patients from a pool of patients with a similar frequency of imaging reports and progress 
notes to the case cohort. Factoring in report frequency alleviated the comparison with 
patients with few or no imaging results, as well as those with dramatically more than the 
average case patient. The two physician raters agreed in 95% of cases. Discordant cases 
were reviewed until consensus was achieved for all patients. We also estimated the 
prevalence of NAFLD in the BioMe cohort by each approach and compared them to 
prevalence estimates that have been reported in similar populations.[23]
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2.4 NAFLD Progression Analyses
As a methodological proof of concept, we then sought to analyze progression time from 
early stage NAFLD without NASH to the point when the treating physician thought the 
patient to likely have progressed to NASH or cirrhosis. Any scientific evaluation of 
progression to NASH would require a biopsy confirming NASH, but the goal here was to 
test a generalizable methodology for understanding progression of a patient condition in the 
eyes of the physician in order to track the flow of patient knowledge between physicians. We 
ordered narrative documents chronologically and then stepped through them, observing 
document type along with the presence of NAFLD and NASH/cirrhosis to observe how 
references moved between note types over time along with progression. From the first note 
on each patient, we stepped through looking for notes with a NAFLD reference and 
documented whether it was a radiology note or a clinic note (a provider note or a discharge 
summary). Once a radiology note had been identified, we tracked how long it took for a non-
radiology clinical note to reference NAFLD. If no further non-radiology notes mentioned it, 
we confirmed that there were additional clinical notes where NAFLD was not mentioned to 
ensure that lack of further reference was not due to a discontinuation of care.
2.5 Knowledge Transfer Analysis
Finally, we explore the relationship between documentation on NAFLD on an imaging test, 
contemporaneous acknowledgment of the possible diagnosis in a clinic note (suggesting that 
a responsible provider acknowledged the possible diagnosis and considered further 
evaluation or management), and subsequent documentation of NASH or cirrhosis in a 
provider note or discharge summary (potentially suggesting disease progression during the 
observation period). With the hypothesis that at least some instances of NASH or cirrhosis 
could be avoided if clinicians took it more seriously, we assess how frequently NAFLD is 
identified but later dropped from the record. Then from this set, we identify patients who 
later developed NASH or cirrhosis, indicating that real damage could have occurred due to 
dropping the subject of NAFLD.
2.6 Statistical Analyses
We calculated summary statistics to determine precision, recall, F1 (a measure of test 
accuracy that considers precision and recall) and F2 scores (placing more emphasis on recall 
and thus emphasizing false negatives more than false positives).[24] Note that F2 is a 
derivative of the F1 combining PPV and Sensitivity, but weighted to prioritize PPV in 
scenarios like this where sensitivity is more important than specificity. We assessed 
ICD-9/10 codes, NLP, and text search for their ability to accurately identify NAFLD patients 
against the reference-standard (manual abstraction), calculating precision, recall, false 
positive rate, F1 and F2 scores for each method. We compared estimates of F1 and F2 scores 
between algorithms using the McNemar test. We used generalized score statistics to 
compare precision, recall and the false positive rate. All data analysis was performed in 
Python (v. 3.6.4 with standard packages). The significance threshold for analyses of 
differences was calculated as a two-sided significance p-value of <0.05.
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3 RESULTS
We included 7,766,654 notes of 38,575 BioMe enrollees from July 8, 2002 through 
December 31, 2017. Parsing with NLP yielded 428,469,717 post-coordinated SNOMED 
expressions describing clinical concepts and related context. Figure 3 shows the queries (or 
query clusters, the case of alcohol users) for the identification of case and control patient 
cohorts.
3.1 Identification of NAFLD by different approaches
We identified 2281 cases of NAFLD using NLP and 10,653 patients appropriate as controls 
for manual review. We also identified 1232 patients by ICD codes and 5489 patients by text 
search. The overlap of patients identified by each approach is shown in Figure 4.
3.1.1 Comparison between different approaches—The summary statistics for a 
manual validation comparing the three patient selection methodologies on 100 cases and 100 
controls are shown in Table 1.
Of the individual approaches, the NLP approach had the best summary statistics with high 
precision (0.89), recall (0.93) and F1 scores (0.91) and low FPR (0.11). Precision of the ICD 
approach was higher but recall and the F1 and F2 scores were significantly lower. The text-
based approach was significantly worse than the NLP approach with respect to all 
parameters (p<0.05), though the difference was far greater in specificity than sensitivity. 
Combining the ICD results with the NLP findings increased sensitivity (.96) no reduction in 
specificity (.89).
3.1.2 Baseline characteristics for NAFLD case and control cohorts—As the 
NLP-based approach had the best overall summary statistics, we used the cases and controls 
identified by this approach for further analyses. The baseline characteristics of the 2281 
cases and 10,653 control participants are shown in Table 2.
3.1.3 Reasons for misidentification of NAFLD—We analyzed reasons for false 
positives and false negatives of the NLP algorithm. Most false positives were due to 
hypothetical or otherwise uncertain references. Three examples are shown in Table 3.
The low precision and F1 score of the ICD-based approach occurred because ICD codes are 
more specific than sensitive. An ICD code is only applied if the physician and hospital 
coders believe that the diagnosis is justifiable as a billing code, but there are many reasons 
(often non-medical) that a problem might not be coded despite its presence. Text search had 
a high false-positive rate due to negations, references in templates and other references not 
indicative of the patient having the problem. The major limitations of each approach are 
explained in Table 4.
3.2 Progression from early-stage NAFLD to NASH/Cirrhosis
Among 2281 patients identified as having NAFLD, 486 (21.3%) were identified as probably 
having NASH. Another 187 were identified as developing cirrhosis, not specifically due to 
NAFLD. Among the 486 documented as having both NAFLD and NASH, 310 patients had 
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NAFL and NASH identified at the same time. For the remaining 176 where NAFLD was 
identified prior to NASH, the median progression time to documentation of NASH was 410 
days.
3.3 Evolution Analyses of Information Flow from Radiology to Clinical Notes
Of the 2281 patients with NAFLD identified in notes, 619 had NAFLD identified in only 
radiology notes (excluding pathology), 1020 had it identified in only clinical documentation 
and 619 again identified it in both radiology and clinical notes. A small number of patients 
(23) had NAFLD identified only in pathology notes, but these references were excluded 
from all analyses. (Figure 5)
Of the 619 patients with NAFLD (fatty infiltration/steatosis, not NASH) identified only in 
radiology notes, 170 (27.5%) were later identified as likely having NASH or cirrhosis. We 
observed a temporal gap averaging 1057 days (range 4 to 4324 days). Of these, 105 were 
presumed to have developed NASH while the remaining 65 were described as having 
cirrhosis.
4 DISCUSSION
We assessed several informatics approaches to identify NAFLD within the EHR data 
compared to manual validation by clinicians in a large, multiethnic cohort. Our observations 
suggest that NLP approaches had the best overall performance compared to ICD and text 
search-based approaches, though there were numerous patients identified by ICD that were 
missed by NLP. In addition, the prevalence of NAFLD (−18% in those patients with imaging 
data) identified by the NLP-based approach was similar to population prevalence using 
nationally representative data, especially considering the ethnic minority predominant 
demographics of the BioMe Biobank. [4,23]
The widespread availability of EHRs in hospital systems provides an opportunity for clinical 
and genomic research, population health analytics, and improvement of patient care through 
clinical decision support.[25,26] However, appropriate use of the large-scale, granular 
information in EHRs depends on accurate and rapid identification of patients with the 
disease of interest. This is especially relevant to the study of NAFLD where the study of its 
natural history has been restricted by the lack of large, longitudinal cohorts with most 
cohorts comprising a few hundred radiological/histologically confirmed NAFLD patients.
[27,28] High-throughput identification of NAFLD with “electronic” follow-up through the 
EHR, could aid in understanding the risk factors for progression to cirrhosis. Analysis of 
progression to NASH was complicated by the fact that due to the complexity of diagnosing 
NASH, a firm diagnosis is often not made. We believe that the methodology could be 
applied better to problems where diagnosis is more certain.
Previous studies have attempted to create algorithms to identify NAFLD through the EHR. 
A study by Corey et al. used limited NLP approaches to define NAFLD within the EHR 
confirmed through radiology reports in combination with ICD codes.[29] They 
demonstrated that the PPV (89%) and NPV (56%) was superior to an approach utilizing 
ICD-9 coding alone or a model incorporating AST/ALT laboratory values. However, the 
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language parsing approach used counted only the occurrences of pre-defined terms related to 
NAFLD without considering critical issues in NLP including negation, context, spelling, and 
acronyms.[30,31] In contrast, we used an integrated NLP approach that fully accounted for 
these issues as applied to EHR documentation. On manual validation, we demonstrated 
improved summary statistics compared to not only ICD-9/10 codes, but also to simple text 
search. We did not attempt a formal comparison of NLP techniques, but rather assessed the 
viability of one particular strategy for two research applications that would be difficult 
without NLP. NLP performed on physicians’ notes will never identify certain truths on the 
patient, rather a representation of what the treating physician believed to be true at the time 
of authoring the note. These should not be confused and hunches should be confirmed by lab 
tests when possible, but this is not possible when looking at data on thousands of patients in 
a retrospective chart review, so one must settle for the best data captured at the point of care.
While conducting analyses of the information flow between several different types of 
documentation where NAFLD may be identified, we found that NAFLD discovered in 
radiology notes was not acknowledged in clinical documentation in approximately one-half 
of the cases. One in ten patients who had NAFLD identified in radiology notes but which 
was not acknowledged in clinical documentation were later documented as having NASH 
without any acknowledgement of other NAFLD in the intervening clinical encounters or 
progress notes.
Previous studies have demonstrated that findings on radiology reports are not uniformly 
acknowledged or pursued by relevant providers.[32,33] This may in part reflect the deluge 
of biomedical information available within EHR systems, which may lead to a breakdown in 
information flow.[34] Although progress has been made on “closing the loop” on these non-
emergent radiology findings,[35] it still is an active area of both research and clinical 
improvement. Our research demonstrates how important findings may not be acknowledged 
or noticed by physicians involved in direct patient care. Further research will look at medical 
problems where follow-up is more critical and inaction could have detrimental consequences 
for the patient. If such breakdowns can be identified, it is critical that the treating physician 
be notified as it could constitute a medical error. How this notification best happens should 
be the subject of additional future work.
Past studies have demonstrated that NLP can be used to obtain valuable data for research 
that can be more accurate than ICD codes.[11,36–38] This study supports these findings, 
identifying NLP as clearly superior for individual phenotype algorithms. As data volume 
and accuracy are critical for big data initiatives, it stands to reason that NLP-derived features 
will yield superior models for these endeavors. Further research is in progress testing the use 
of these features in deep learning models to predict various clinical outcomes, such as the 
identification of NAFLD patients before the treating physician has mentioned the possibility 
in the notes.
Our research should be interpreted in the context of its limitations. First, we used only one 
NLP tool for analyses. Future work should attempt a comprehensive evaluation and 
comparison of different NLP software for various use cases. We anticipate that the best 
software would depend on the use case and setting. This approach could be accomplished 
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with any NLP software capable of accurately mapping to and querying any clinical 
terminology as expressive as SNOMED CT/DL, however no other tool capable of this task 
was available at the time of publication. Second, we used data from only one medical center 
thus the applicability of our findings to other settings remains to be determined. That said, 
the Mount Sinai medical system has a large network of providers from different specialties 
and each with their own unique writing style, therefore we believe this electronic 
phenotyping approach can be successfully used across multiple healthcare systems. [39] 
Third, in the analyses of information flow from radiology to clinical documentation, it is 
possible that patients may have been receiving care outside of our hospital system and thus 
not be captured by our EHR. However, we limited this possibility by conducting a subset in 
which patients had at-least one clinical encounter after the radiology identification of 
NAFLD. Lastly, the gold standard for diagnosis of NASH is liver biopsy, however only 22 
patients in our cohort had one performed. Our progression analysis therefore can only be 
reflective of the physician’s interpretation of the patient’s NAFL to NASH progression. 
From the perspective of studying actual disease progression, these methods are clearly 
limited by the physicians’ understanding of their patients and the availability of all patient 
notes.
5 CONCLUSIONS
In summary, we demonstrate that NLP-based approaches have superior accuracy in 
identifying NAFLD within the EHR compared to ICD/text search-based approaches. There 
is lack of acknowledgement in clinical documentation of NAFLD findings in radiology 
reports and a significant number of these patients are later reported to have NASH. As 
medical practice becomes more specialized and patient care is provided by more physicians, 
the opportunities for information loss at patient handoffs increase. Our observations suggest 
that NLP-based approaches have the potential to identify dropped observations in EHR data 
that warrant additional follow-up.
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HIGHLIGHTS
• NAFLD IS POORLY DOCUMENTED IN STRUCTURED DATA. WE 
COMPARE HOW WELL WE CAN IDENTIFY IT USING A NATURAL 
LANGUAGE PROCESSING TECHNIQUE AGAINST STRUCTURED 
DATA AND SIMPLE TEXT SEARCH.
• NAFLD CAN PROGRESS TO NASH AND TRIGGER CIRRHOSIS. WE 
EXAMINE OUR ABILITY TO MEASURE DISEASE PROGRESSION.
• CONTINUITY OF CARE BREAKS DOWN IF CRITICAL CLINICAL 
INFORMATION IS NOT PASSED ON FROM ONE CLINICIAN TO THE 
NEXT IN NOTES. WE LOOK FOR BREAKDOWNS IN THE 
KNOWLEDGE CHAIN, IDENTIFYING MANY PATIENTS WHERE 
NAFLD WAS IDENTIFIED BUT DROPPED, AND THE PATIENT LATER 
WENT ON TO DEVELOP NASH OR CIRRHOSIS.
Van Vleck et al. Page 13
Int J Med Inform. Author manuscript; available in PMC 2020 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
SUMMARY TABLE
What was already known on the topic
• Notes contain deep clinical information not captured by structured data.
• NLP can be used extract data from clinical notes not captured in structured 
data.
• SNOMED is a highly descriptive and well organized terminology that can be 
leveraged for all sorts of medical logic.
• NAFLD is a growing public health problem, not always taken seriously.
What this study added to our knowledge
• Even when NAFLD is known to be present, doctors code for it infrequently. 
SNOMED-based NLP is good at identifying those instances where they do 
not.
• NAFLD is frequently not mentioned in notes even when identified by a 
previous physician. This can lead to the development of more serious diseases 
that could have been avoided.
• Using NLP, we can identify breakdowns in communication at the point of 
care that can lead to patient problems and/or medical errors if left unchecked.
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Figure 1: 
A SNOMED expression output by the NLP system on the phrase “liver disease”, including 
associated metadata describing the context. When used as a query, this expression would 
identify all references to any liver disease blown present or previously present.
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Figure 2: 
Study design for data extraction and manual chart review assessing automated identification 
of patients with NAFLD
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Figure 3: 
NLP SNOMED queries for case and control cohorts
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Figure 4: 
Overlap of patients identified by three different approaches
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Figure 5: 
Distribution of note types referencing NAFLD, counted by patient with at least one note of 
each type referencing NAFLD
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Table 1:
Accuracy of NLP identification of NAFLD patients relative to ICD codes and basic text search
NLP ICD Selection Text Search NLP & ICD
Sensitivity 0.93 0.32 0.81 .96
Specificity 0.89 0.99 0.84 .89
PPV 0.89 0.97 0.83 .90
FPR 0.11 0.03 0.17 .10
F1 0.91 0.48 0.82 .93
F2 0.92 0.37 0.81 .95
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Table 2:
Baseline characteristics of NAFLD cases and controls, all values: p ≤0.01
Cases (n=2281) Controls (n=10,653)
Mean Age 59.8 59.5
% Male 42% 39%
Race
African American 20% 30%
Caucasian/European 23% 22%
Asian 2% 2%
Hispanic 48% 41%
Other 6% 5%
Mean liver serology at baseline
Aspartate Aminotransferase 45.7 39.7
Alanine Aminotransferase 48.5 35.9
Baseline Comorbidities
Diabetes Mellitus, n (%) 1233 (40.7%) 3524 (27.6%)
Hypertension, n (%) 2079 (68.6%) 7898 (61.9%)
Mean Body Mass Index 31.8 29.2
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Table 3:
Review of NLP fcdse-positives
Problem Example
Hypothetical reference Nonspecific hepatic parenchymal change, such as, but not limited to, fatty liver
Mis-hyphenated word Associated enhancing right paravertebral 5.6 cm soft issue with calcific rim at the L1/L2 level effacing the peri-hepatic fat
Uncertain Reference Liver is nodular in contour, suggestive of cirrhosis. There is diffuse hypoattenuation of the liver likely representing hepatic steatosis
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Table 4:
Strengths and limitations of patient selection modalities
Methodology Strengths Weaknesses
ICD query Very high specificity Can be 
standardly used
Low sensitivity, can’t differentiate between NASH and simpler NAFL
Text search Moderately high sensitivity and 
specificity
Unpredictable as it depends on identifying the exact phrases used by note authors 
Scalability issues since manual verification of exact search strings to be used is must 
be performed
NLP High sensitivity and specificity Requires access to NLP infrastructure, especially one capable of post-coordinating 
SNOMED expressions
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